As of November 8, 2026, Q32 Bio Inc. is a publicly traded company (Nasdaq: QTTB). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 13.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BVF Partners (9.99%), RA Capital (9.8%), Boxer Capital Management, LLC (7.9%) (Schedule 13D/A, July 20, 2026).
Is this your company?
About to sign with, pay or invest in Q32 Bio Inc.? See the free Snapshot first.
Free to see. No signup.
Is Q32 Bio Inc. a real, registered company?
- Q32 Bio Inc. files with the SEC under CIK 1661998 (its SEC filings).
- Its shares are listed under the ticker QTTB on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Q32 Bio Inc. in our court records and SEC 8-K records (as of 2026-11-08).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Boxer Capital Management, LLC (filed 2026-11-06).
Who are Q32 Bio Inc.'s owners and officers?
Q32 Bio Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | Opaleye Management Inc. | 3.76% |
| Schedule 13G/A, 2026-11-06 | Boxer Capital Management, LLC | 7.9% |
| Schedule 13G, 2026-10-28 | Bank Of America Corp /De/ | 7.4% |
| Schedule 13G, 2026-10-09 | Frazier Life Sciences Public Fund, L.P. | 5.9% |
| Schedule 13G/A, 2026-08-14 | Point72 Asset Management, L.P. | 4.95% |
| Schedule 13G/A, 2026-08-14 | Sirenia Capital Management LP | 0% |
| Schedule 13G/A, 2026-07-31 | Opaleye Management Inc. | 5.49% |
| Schedule 13D/A, 2026-07-20 | Orbimed Advisors LLC | 13.9% |
| Schedule 13G, 2026-07-10 | Boxer Capital Management, LLC | 13.3% |
| Schedule 13G/A, 2026-07-06 | The Carlyle Group Inc. | 4.1% |
| Schedule 13G, 2026-06-04 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G, 2026-06-04 | Ra Capital Management, L.P. | 9.8% |
Questions about who owns Q32 Bio Inc.
Who owns Q32 Bio Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Q32 Bio Inc.: Orbimed Advisors LLC (13.9%, Schedule 13D/A, filed 2026-07-20), Bvf Partners L P/Il (9.99%, Schedule 13G, filed 2026-06-04), Ra Capital Management, L.P. (9.8%, Schedule 13G, filed 2026-06-04), Boxer Capital Management, LLC (7.9%, Schedule 13G/A, filed 2026-11-06) and Bank Of America Corp /De/ (7.4%, Schedule 13G, filed 2026-10-28); 1 more is listed above.
Who are the largest shareholders of Q32 Bio Inc.?
By the share each holder's latest filing reports, the largest holders of Q32 Bio Inc. on this page are Orbimed Advisors LLC (13.9%), Bvf Partners L P/Il (9.99%) and Ra Capital Management, L.P. (9.8%).
When did Orbimed Advisors LLC buy into Q32 Bio Inc.?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-07-20, reporting 13.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Q32 Bio Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Q32 Bio Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Q32 Bio Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Q32 Bio Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 625,000 shares (2.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-06-01).
- Atlas Venture Associates Opportunity III, L.P.: 625,000 shares (2.1% of shares outstanding), on a joint filing (Form 3, 2026-06-08).
- Atlas Venture Opportunity Fund Ill, L.P.: 625,000 shares (2.1% of shares outstanding), on a joint filing (Form 3, 2026-06-08).
- Atlas Venture Associates Opportunity III, LLC: 625,000 shares (2.1% of shares outstanding), on a joint filing (Form 3, 2026-06-08).
- OrbiMed Capital GP VII LLC, a director and 10% owner: 625,000 shares (2.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-01).
Shares outstanding: 29,923,882 as of 2026-10-31, from the company's latest SEC cover page.
How much has Q32 Bio Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2025-12-01).
Keep reading
More on Q32 Bio Inc. and the records around it.
Q32 Bio Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Boxer Capital Management, LLC also filed stake reports on 1 other company: Surrozen, Inc./DE (Oct 2026)
- Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), Allogene Therapeutics, Inc. (Feb 2026)
- Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), GENERATION BIO CO. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/q32-bio